Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial
Clinical Rheumatology, ISSN: 1434-9949, Vol: 38, Issue: 9, Page: 2461-2471
2019
- 9Citations
- 41Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef1
- Captures41
- Readers41
- 41
- Mentions2
- News Mentions2
- News2
Most Recent News
Safety and Efficacy of Diacerein Treatment in RA Examined in Pilot Study
Diacerein may be a safe and efficacious treatment option in patients with rheumatoid arthritis (RA) who are inadequate responders to methotrexate (MTX) therapy, according to
Article Description
Objective: To evaluate the efficacy and safety of diacerein in patients with rheumatoid arthritis (RA) who are methotrexate inadequate responders (MTX-IR). Method: In this pilot, multicenter, double-blind, placebo-controlled trial, MTX-IR RA patients were randomized to either diacerein or matching placebo as add-on treatment to MTX for 24 weeks. Efficacy and safety were evaluated every 4 weeks until week 28. Primary and secondary efficacy endpoints were the percentage of patients achieving the ACR20 criteria and a moderate EULAR response at week 24, respectively. Results: Forty patients were equally randomized to both study treatments; 16 and 19 participants completed the study in the diacerein and the placebo arms, respectively. Baseline characteristics were similar in both groups, except that tender joint count, DAS28-ESR score, and non-steroidal anti-inflammatory drug consumption were higher in the placebo arm. The ACR20 response at week 24 was similar in the diacerein and placebo groups (65% vs 45%, P =.20). However, treatment response according to the EULAR criteria was better in patients taking diacerein (75% vs 25% of moderate response, P =.002). In the 35 patients with assessments through week 28, diacerein was superior to placebo in ACR20 at weeks 24 and 28 (both 81% vs 47%, P =.04). Incidence of adverse events was comparable in both arms, with only chromaturia being more common with diacerein than placebo (40% vs 10%, P =.03). Conclusions: These preliminary results show the potential benefits of diacerein on pain, joint function, and disease activity in MTX-IR RA patients. Trial registration: ClinicalTrials.gov Identifier: NCT01264211Key Points• Diacerein has shown positive effects on rheumatoid arthritis symptoms.• A good safety profile of diacerein has been observed when it was administered as add-on therapy to methotrexate in patients with rheumatoid arthritis.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85066092948&origin=inward; http://dx.doi.org/10.1007/s10067-019-04587-1; http://www.ncbi.nlm.nih.gov/pubmed/31104217; https://clinicaltrials.gov/ct2/show/NCT01264211; http://link.springer.com/10.1007/s10067-019-04587-1; https://dx.doi.org/10.1007/s10067-019-04587-1; https://link.springer.com/article/10.1007/s10067-019-04587-1
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know